Patients with OSA may be at increased risk for adverse respiratory events from intravenous benzodiazepine sedation. Intravenous benzodiazepine sedation should be used with caution. (2B)

There is a lack of evidence to assess adverse effects of α-2 agonists in the population with OSA（Evidence level:C；Recommendation grade:No Recommendation）.

When applicable, regional anesthesia is preferable over general anesthesia in patients with OSA. (1B)

We suggest against the performance of neuraxial blocks in patients with a CrCl of less than 30mL/min. (2C)

The use of herbal medications does not create a level of risk that will interfere with the performance of neuraxial block. We recommend against the mandatory discontinuation of these medications or avoidance of regional anesthetic techniques in patients in whom these medications have been administered. (1C)

Based on the elimination half-life, we suggest that neuraxial techniques be avoided for 3 hours after discontinuation of cangrelor. (2C)

Based on the elimination half-life, we suggest discontinuing extended-release dipyridamole for 24 hours prior to neuraxial block. Aspirin may be continued perioperatively. (2C)

Based on the elimination half-life, we suggest that neuraxial techniques be avoided for 2 days after discontinuation of cilostazol. (2C)

Ticagrelor therapy may be resumed immediately after needle placement/catheter removal, provided a loading dose of the drugs is not administered. If a loading dose is administered, we suggest a time interval of 6 hours between catheter removal and administration. (2C)

Neuraxialcatheters should not be maintained with ticagrelor because of the rapid onset. (2C)